top of page
Fund Manager Summary on Clarity Pharmaceuticals Ltd (ASX:CU6)
In February 2026, Pengana Capital commented that Clarity Pharmaceuticals Ltd (ASX:CU6) had released abstract data showing its 64Cu‑SAR‑bisPSMA diagnostic detected lesions in 78% of patients versus 36% for a 68Ga tracer, with imaging driving treatment‑plan changes in 44% of cases and supporting an estimated USD 3 billion prostate diagnostic market that Clarity could capture 10–20% of. Fund managers broadly view CU6 as a differentiated radiotheranostics developer with near‑term, high‑impact catalysts (Co‑PSMA head‑to‑head, AMPLIFY and CLARIFY Phase‑3 diagnostic readouts and SECURE therapeutic cohort data) and a structural opportunity from more sensitive next‑day Cu‑64 imaging (12.7‑hour half‑life) that has shown larger lesion detection and meaningful rates of treatment‑change in early studies; recent equity raises (~AUD 200–203m) and previous cash positions (c.$106m, pro forma ~$288m reported) materially extend runway and reduce immediate dilution risk, while industry backdrops (US biotech sell‑offs, heightened short interest and episodic regulatory uncertainty) drive pronounced share volatility and create both funding and timing risks. Managers flag execution and regulatory risk (trial and approval pathways, commercial roll‑out logistics), competition from established players in diagnostics and scale challenges for therapeutics, but also note actionable strategic levers: additional non‑equity deals/licensing, US manufacturing agreements, selective capital raises, and potential M&A interest if pivotal data repeats; the consensus is data‑driven—positive Phase‑3 and SECURE readouts should materially derisk value and attract partners or market share, whereas disappointing results or persistent market pressure/short squeezes would keep valuation under stress.
Commentary From The Managers
There are 23 insights from 7 fund managers regarding their investment in Clarity Pharmaceuticals Ltd (ASX:CU6) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Pengana Capital
28 Feb 2026
$3.39
Summary
- Pengana Capital believes the Co‑PSMA abstract materially strengthens Clarity's clinical case and continues to hold because the 64Cu tracer delivered substantially higher lesion detection with a meaningful impact on treatment decisions, supporting the company's valuation.
- Market reaction: Clarity Pharmaceuticals rose 17% after releasing the abstract ahead of the European Association of Urology (13–16 March) presentation.
- Trial context: The Co‑PSMA trial compares 64Cu‑SAR‑bisPSMA (Clarity) against 68Ga‑PSMA‑11 (used by Telix) in the post‑prostatectomy PSA recurrence setting to guide additional treatment such as radiotherapy.
- Key efficacy data: 64Cu detected lesions in 78% (39/50) of patients versus 36% (18/50) for 68Ga.
- Clinical impact: The more sensitive imaging led to treatment‑plan changes in 22 of 50 patients (44%); discussions with clinicians indicate a 20–30% change rate would already be considered clinically meaningful.
- Market opportunity: The prostate cancer diagnostic market could reach ~USD $3 billion by 2029.
- Commercial potential and valuation: Clarity could reasonably capture 10–20% of that market, which alone supports the company's current market capitalisation of approximately AUD $1.3 billion.
Blackwattle Investment Partners
30 Nov 2025
$3.49
Summary
- Clarity Pharmaceuticals is an emerging healthcare company specializing in nuclear medicine.
- The company experienced a share price contraction of -26.3%, influenced by broader trends in growth stocks.
- In October, shares rose 37.6% following a positive trial result for its Prostate cancer diagnostic product.
- The trial demonstrated that for every lesion identified by the competitor Telix, Clarity's product found 1.5 lesions, indicating significantly higher sensitivity.
- This advancement could revolutionize the industry by enabling earlier treatment of cancer, leading to less harmful therapies.
- Although the study was small, it sets the stage for a full Phase-3 FDA trial expected in early 2026.
- If successful, Clarity could become the standard of care for prostate cancer diagnostics in a lucrative market.
- Blackwattle Investment Partners continues to hold because they see potential for significant growth and plan to add to their position at the right time.
Pengana Capital Group
30 Nov 2025
$3.49
Summary
- Pengana Capital Group updates its investment thesis on Clarity Pharmaceuticals.
- Share price reaction: Clarity fell 26% on limited news, prompting a reassessment of near-term drivers.
- Upcoming data (Q1): Expect readouts from the Co-PSMA study (diagnostic comparison versus Telix) and the SECURE therapeutic study; each could act as meaningful catalysts.
- Regulatory timeline: Best-case pathway could lead to FDA approval in early 2027, while a more likely outcome is late 2027 or 2028.
- Market opportunity: The prostate cancer diagnostic market is ~USD 2.5bn today and is expected to reach ~USD 3bn within two years; the market is currently dominated by Telix and Lantheus.
- Commercial potential: Pengana assesses a 10% market share as achievable over time, which would imply a valuation materially above the current AUD 1bn market cap.
- Key risks: Regulatory timing slips, trial outcomes that underperform expectations, and competitive pressure from incumbent players.
- Neutral reminder: This summary reflects Pengana Capital Groups updated investment thesis and is for informational purposes only; it is not financial advice.
Blackwattle Investment Partners
31 Oct 2025
$4.90
Summary
- Clarity Pharmaceuticals is an emerging healthcare company focused on nuclear medicine.
- Shares rose 37.6% in October following a positive trial result for its prostate cancer diagnostic product.
- The trial involved a head-to-head comparison with Telix, demonstrating that Clarity's product identified twice as many lesions as the incumbent product.
- This higher sensitivity allows for the detection of smaller tumors, potentially revolutionizing cancer treatment.
- Earlier detection could enable less harmful treatments, benefiting patient health.
- While the study was relatively small, it sets the stage for a full Phase-3 FDA trial result expected in early 2026.
- If successful, Clarity could become the standard of care for prostate cancer diagnostics, tapping into a large and valuable market.
Pengana Capital Group
31 Oct 2025
$4.90
Summary
- Clarity Pharmaceuticals rose 37% following initial data release from its Co-PSMA study.
- Study compared Cu-64–based prostate cancer imaging agent with a Ga-68 agent.
- Early results indicated a statistically significant increase in cancer lesions detected using Clarity’s product.
- Full details are expected to be released at a conference in Q1 next year.
- Pengana Capital Group continues to hold its position based on these promising developments.
Endeavor Asset Management
31 Oct 2025
$4.90
Summary
- Endeavor Asset Management sold their investment in Clarity Pharmaceuticals (CU6) after a strong performance.
- The decision followed the announcement of favourable results from the Co-PSMA clinical trial.
- The trial compared Clarity’s copper-based diagnostic agent to the current standard of care from Telix Pharmaceuticals.
- It successfully met its primary endpoint, identifying a statistically higher number of PSMA-positive prostate cancer lesions than TLX.
- This outcome reinforces the superior diagnostic performance of Clarity’s platform.
- The results provided a meaningful validation of Clarity’s underlying radiopharmaceutical technology.
- Endeavor exited during the month for a healthy profit.
Ausbil Investment Management
30 Sept 2025
$3.56
Summary
- Ausbil initiated a position in Clarity Pharmaceuticals (CU6) in July, despite the stock falling from the placement price.
- Clarity has a genuinely differentiated product portfolio poised to enter a large and growing radiopharmaceutical market.
- There are similarities to Telix’s product portfolio from several years ago, indicating potential growth.
- The company raised approximately $200m in equity in July, which has de-risked the balance sheet and provides over 2 years of runway toward commercialization.
- Although the stock initially performed well post-raise, it faced a sell-off due to concerns regarding ASX 200 index removal and weak results from competitors.
- Since 30 September, the stock has rallied approximately 30% above the placement price.
Endeavor Asset Management
31 July 2025
$4.37
Summary
- Endeavor Asset Management notes the strong performance in healthcare, particularly with Clarity Pharmaceuticals (CU6) and Neuren Pharmaceuticals (NEU) rising significantly in July.
- In February, the fund rotated out of CSL, reallocating capital into CU6 and NEU, believing these emerging names present greater upside potential.
- Since the switch, CU6 and NEU have returned +23% and +24% respectively, outperforming CSL, which only rose +1%.
- Clarity Pharmaceuticals was particularly notable in July, with strong anticipation building for its upcoming co-PSMA trial, which will compare its prostate cancer imaging agent to the current standard of care.
- The company completed a $203 million equity raise during the month at a premium to the prevailing share price, indicating strong investor confidence.
- With a well-capitalized position and multiple opportunities within its oncology pipeline, Endeavor Asset Management sees significant upside potential should the coPSMA trial yield favorable results.
Pengana Capital Group
31 July 2025
$4.37
Summary
- Clarity Pharmaceuticals has experienced a 75% rise following the full recruitment announcement of the CoPSMA study.
- The study is being conducted at St Vincent’s Hospital and compares Clarity’s prostate cancer diagnostics with those of Telix.
- It aims to determine if Clarity’s more sensitive scan impacts treatment decisions for prostate cancer patients.
- Clarity has raised $200 million, enhancing its financial position.
- This funding will support the completion of two major Phase 3 studies for its prostate cancer diagnostic.
- Clarity is well-positioned to potentially reach breakeven in the near future.
- Pengana Capital Group continues to hold its investment due to these positive developments.
SG Hiscock & Company
31 July 2025
$4.37
Summary
- Clarity Pharmaceuticals (ASX: CU6) experienced a significant gain of 74.8% in July, driven by a successful $203m capital raise.
- The capital raise was well-received, completing its institutional placement at a 2.2% premium to the prior close and an 18% premium to its 15-day VWAP.
- CU6 now has a pro forma cash balance of ~$288m, fully funding its Phase III trials and commercial readiness activities.
- The upcoming Co-PSMA head-to-head trial is a key near-term catalyst, with data expected soon comparing its 64Cu-SAR-bisPSMA diagnostic to the standard-of-care 68Ga-PSMA-11.
- A positive result in this trial would enhance CU6’s position as a differentiated, next-generation radiopharmaceutical alternative.
- Looking ahead, CU6 is advancing two registrational diagnostic trials: AMPLIFY (final readout expected 4QCY25) and CLARIFY (1HCY26).
- CU6 has received Fast Track Designations from the FDA and established new US manufacturing agreements, positioning itself for a successful commercial rollout.
- While execution risk exists across clinical and regulatory fronts, CU6’s strong cash position and advanced pipeline support its potential to reshape prostate cancer imaging and therapy.
- SG Hiscock & Company continues to hold because of CU6's robust funding and promising clinical developments.
Frazis Capital Partners
18 July 2025
$3.89
Summary
- Frazis Capital Partners observes that Clarity stock has experienced a classic momentum unwind, where initial higher prices attracted buyers, followed by lower prices attracting sellers.
- Despite the momentum unwind, Frazis Capital Partners believes the price will stabilize at a level where no further selling occurs, creating an investment opportunity.
- The average purchase price for Clarity shares was $1.69 in April, reflecting a strategic entry point.
- Serious revenues for Clarity are anticipated in 2-3+ years, but the perception of timeframes is shifting as 2027 approaches.
- Frazis Capital Partners is testing the waters on whether the current biotech liquidation phase has concluded.
- A recent call with Dr. Oliver Sartor highlighted the significant unmet need in diagnosing prostate cancer, particularly for the 600,000 men in the U.S. who test negative on current screens.
- Patients are actively seeking better diagnostics, indicating strong demand for Clarity’s offerings, despite skepticism from some investors about competing with established incumbents.
- Clarity's stock has more than doubled from its lows but is still approximately 150% below its peak last year, suggesting potential for recovery.
Frazis Capital Partners
23 Apr 2025
$2.08
Summary
- Frazis Capital Partners observes that Clarity Pharmaceuticals is affected by broader sell-offs in the biotech sector, particularly following negative results from Opthea.
- Liquidations by funds and retail investors have increased due to market momentum unwinding.
- Clarity has substantial growth potential with approximately $20 billion in diagnostics and even larger opportunities in therapeutics.
- The company's current market cap of $400 million significantly underplays its potential against the market opportunity.
- Short selling has created liquidity and potential for future funding, however, it poses risks for shortsellers as momentum can reverse.
- With $106 million in cash and an $11 million non-dilutive R&D grant, Clarity is well-positioned to extend its development timeline.
- Positive clinical updates include improved patient outcomes and ongoing trials that could validate Clarity's treatments.
- Noteworthy therapeutic data includes disease control rates of 78% in patients who had previously undergone multiple treatments.
- Clarity's diagnostic agent shows promise, having identified lesions better than standard diagnostics and may lead to significant treatment changes.
- Upcoming clinical trial readouts over the next year are expected to enhance clarity on Clarity's market position.
- Both diagnostics and therapeutics markets show potential—diagnostics forecasted at $3 billion and therapeutics exceeding $5 billion.
- Frazis Capital Partners recently reinstated a holding in Clarity, now constituting ~8% of their portfolio, indicating confidence in the company's future growth.
Pengana Capital Group
31 Mar 2025
$2.11
Summary
- Clarity Pharmaceuticals has experienced a significant decline of 40% in share price, despite a buy rated report from broker Barrenjoey with a target of $8.7/share.
- Shares previously peaked at $8.65 in September last year; Pengana Capital Group sold much of its holding during that rally but has since rebuilt its position.
- The prostate cancer radio diagnostic market is valued at USD 2bn and is growing, with key players being Telix and Lantheus.
- Pengana Capital Group anticipates that Clarity will receive approval by late 2026 and capture at least 10% market share.
- Clarity's current valuation of AUD $530mln appears attractive compared to Telix and Lantheus, which have market values of AUD $9bn and $11bn, respectively.
- Professor Louise Emmet is conducting a diagnostic study comparing Clarity's technology with a generic version of Telix’s Illucix, which could be pivotal.
- The study aims to determine if a Clarity scan could change treatment plans for more than 20-30% of patients compared to G-68 scans.
- Clarity has previously demonstrated the ability to detect smaller lesions than G-68, potentially leading to better treatment outcomes.
- CEO Alan Taylor's recent interview highlighted the potential for Clarity to capture a significant market share if the study is successful.
- The SECURE prostate cancer therapy study is currently enrolling an additional 24 patients, with promising results observed so far.
- Despite a recent lull in radiopharmaceutical deals, Pengana Capital Group views Clarity as a likely takeover target.
Pengana Capital Group
31 Dec 2024
$4.17
Summary
- Clarity Pharmaceuticals experienced a 35% decline, potentially influenced by Janux data.
- Pengana Capital Group utilized this market weakness to increase their position.
- Prior to this, the holding was significantly reduced at higher levels.
Pengana Capital Group
30 Sept 2024
$8.38
Summary
- Clarity Pharmaceuticals rose 16% following positive data from Cohort 4 of its SECURE prostate cancer radiotherapy dose escalation study.
- No dose limiting toxicities were observed at the higher dose.
- Two out of three evaluable patients showed significant results: one had a 92.3% PSA decline and another had a decline of greater than 60%.
- Both patients had undergone multiple prior lines of treatment.
- Pengana Capital Group continues to hold due to the promising results and expects another 3 patients to be dosed in the coming month or two.
- Additionally, 14 more patients are likely to begin treatment next year.
Pengana Capital Group
31 July 2024
$6.37
Summary
- Clarity Pharmaceuticals has seen a 17% rise in share price following a supply agreement with Terra Power, a US firm backed by Bill Gates.
- The agreement involves Actinium 225, a promising medical isotope known for delivering high radiation doses over short distances, enhancing treatment targeting.
- Clarity is currently focusing on Copper 67 in its clinical studies.
- The recent surge in M&A activity within the Actinium-related therapeutic sector may position Clarity Pharmaceuticals as a more attractive acquisition target.
- Pengana Capital Group continues to hold its position in Clarity Pharmaceuticals due to these developments.
Pengana Capital Group
31 Mar 2024
$2.78
Summary
- Pengana Capital Group continues to hold an investment in Clarity Pharmaceuticals Ltd.
- Clarity Pharmaceuticals recently experienced a 5% decline in share price.
- The company successfully raised $121 million in capital, in which Pengana Capital Group participated.
- The funding will support the development of Clarity's product pipeline.
- Particular focus is on the ongoing Secure study, which is a dose escalation study for a prostate cancer therapeutic.
- Further data from the next three patients in the Secure study is expected by mid-year.
Pengana Capital Group
29 Feb 2024
$2.89
Summary
- Clarity Pharmaceuticals, the Fund’s second largest holding, rose 23% after reporting results from its Phase 2 COBRA study in prostate cancer diagnosis in metastatic disease.
- The results highlight a significant improvement in the ability to detect cancer lesions, particularly small sized tumors, compared to the current standard of care products from Telix and Lantheus.
- A further large scale phase three trial will be required to prove this, but the data looks very encouraging.
- Pengana Capital Group continues to hold because we expect the company will soon report further data from a dose escalation study in its prostate cancer therapeutic trial SECURE, which is eagerly anticipated by the market.
Pengana Capital Group
31 Jan 2024
$2.34
Summary
- Pengana Capital Group reports a significant rise in Clarity Pharmaceuticals Ltd, with shares up 24% this month.
- The stock has increased nearly 300% since Pengana Capital Group invested five months ago.
- Recent global takeovers in the radiotherapy sector enhance the relative attractiveness of Clarity’s potential.
- Sell-side analysts have released reports upgrading their price targets for Clarity Pharmaceuticals.
- Competing company Telix Pharmaceuticals saw a 14% increase following a positive revenue update.
- The growth in Telix's prostate cancer diagnostic market further underscores the opportunity within the sector.
Pengana Capital Group
31 Dec 2023
$2.10
Summary
- Pengana Capital Group notes a significant rise in Clarity Pharmaceuticals Ltd, which increased by 33% this month and is up 240% since the initial investment four months ago.
- The surge was primarily influenced by the acquisition of RayzeBio by Bristol Myers for USD 4.1 billion.
- While RayzeBio's lead product is more advanced, it targets a smaller market (Neuroendocrine Tumours) with 18,000 cases per year compared to prostate cancer's 288,000 new cases.
- Another relevant acquisition was Point Biopharma by Lilly in October, indicating interest in the radiotherapy sector.
- Pengana Capital Group believes Clarity Pharmaceuticals could be a potential takeover target in the coming year.
- Clarity continues to advance its prostate cancer dose escalation study, SECURE, which is expected to generate further positive data.
Pengana Capital Group
30 Nov 2023
$1.42
Summary
- Recent portfolio addition: Clarity Pharmaceuticals, a company focused on radiopharmaceuticals and diagnostics.
- Performance: The stock rose 36% in the past month and has returned 70% over the last three months since acquisition.
- Main driver of returns: Phase I/IIa dose escalation study SECURE for prostate cancer therapeutic product SAR-bisPSMA.
- Signs of efficacy: The study is showing substantial signs of efficacy with few side effects, although in a small patient group.
- Future outlook: Anticipation of further data readouts in the coming months, expected to attract interest from both the medical and investment communities.
Pengana Capital Group
31 Aug 2023
$1.09
Summary
- Pengana Capital Group recently added a new holding in Clarity Pharmaceuticals, an Australian radiotherapy company, via a placement at $1/share.
- The investment has already returned 17% in September.
- Clarity has developed a radiation diagnostic and therapy platform using proprietary copper-64 and copper-67 isotopes.
- Copper isotopes offer a long shelf life, providing logistical advantages over existing Gallium and Florine isotopes.
- These isotopes are highly targeted for diagnosing and treating cancer cells.
- Clarity has five products, with SAR-bisPSMA for prostate cancer being particularly noteworthy.
- SAR-bisPSMA is currently in a phase 2 dose-escalation study called SECURE, with early results showing strong efficacy and low side effects.
- Clarity's single-dose treatment has demonstrated better responses compared to the standard of care, Pluvicto, which requires six doses.
- Continual news flow from the SECURE study is expected over the coming months.
- Clarity Pharmaceuticals listed at $1.4/share in August 2021 and is currently trading at $1.17, despite a recent 50% rally.
- The market value of Clarity is approximately AUD$310 million.
- Pengana Capital Group views Clarity's position as promising, considering Novartis acquired Endocyte for USD2.2 billion to gain the leading prostate radiotherapy drug.
- Clarity is expected to be in a similar position by the end of next year.
Pengana Capital Group
31 May 224
$2.16
Summary
- Clarity Pharmaceuticals rose 81% following a significant clinical response in a cancer patient post-capital raise.
- The company was the first to raise capital on April 8th at $2.55 and is now trading at $5.22.
- Capital raises can absorb short-term demand for shares, leading to temporary price suppression.
- The notable rise followed the report of a patient with metastatic castrate-resistant prostate cancer (mCRPC) being completely cleared of the disease after two doses of Clarity’s radiation therapy.
- The patient experienced few side effects, highlighting the drug's potential.
- Complete responses are rare in cancer studies, making the share price reaction notably positive.
- This positive response occurred shortly after a capital raising that had temporarily impacted share prices.
- The company is increasing the drug dosage in the ongoing SECURE study, with more data expected in the next two months from a new cohort of patients.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Clarity Pharmaceuticals Ltd (ASX:CU6)?
Fund managers including Frazis Capital Partners, Pengana Capital Group, SG Hiscock & Company, Endeavor Asset Management, Ausbil Investment Management, Blackwattle Investment Partners and Pengana Capital have invested in Clarity Pharmaceuticals Ltd (ASX:CU6).
Why do fund managers invest in Clarity Pharmaceuticals Ltd?
Fund managers invest in Clarity Pharmaceuticals Ltd due to its strong growth prospects in the lucrative prostate cancer diagnostic and therapeutic sectors. With a market cap of approximately $400 million, the company is seen as undervalued given the potential market opportunities worth billions. Its innovative diagnostic technology has shown superior performance in trials, which could lead to significant revenue generation. Additionally, Clarity's solid cash position supports its research and development projects, reducing investment risk and enhancing the overall risk/reward profile.
What happened to Clarity Pharmaceuticals Ltd (ASX:CU6)?
Fund managers see significant potential in Clarity Pharmaceuticals Ltd due to its innovative copper-based prostate cancer diagnostic, which outperforms the current market leader, Telix, in detecting cancer lesions. The recent trial results indicated that Clarity's product detected 1.5 times more lesions, highlighting its superior sensitivity and potential to transform early cancer treatment. With a solid financial position bolstered by a recent capital raise and anticipated forthcoming data that could drive FDA approval, Clarity is well-positioned in the growing $3 billion prostate cancer diagnostic market, attracting investor interest.
What is the short interest in Clarity Pharmaceuticals Ltd (ASX:CU6)?
The short interest in Clarity Pharmaceuticals Ltd (ASX:CU6) is 6.07% which makes it the 31st most shorted stock on the ASX. Of the 372.0M shares that Clarity Pharmaceuticals Ltd has on issue, 22.6M have been sold short.
What does Clarity Pharmaceuticals Ltd (ASX:CU6) do?
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
faqs
q1
q2
q3
q4
q5
bottom of page